In order to obtain sufficient doses of vaccine to protect the most vulnerable populations, such as health professionals and the elderly, the next step in the partnership is to confirm the intention of potential self-financing participants to participate by August 31 and translate them into binding commitments to join the COVAX facility (COVAX facility). , with the first instalments to follow and no later than October 9, 2020. CEPI and SK Bioscience will expand their cooperation for the development of next-generation COVID 19 vaccines, which would fund vaccines from their own public budgets, have so far presented expressions of interest before the 31 August deadline to confirm their intention to participate. They will work with 92 low- and middle-income countries that will be supported by the CMA when it reaches its funding targets. Together, this group of 172 countries represents more than 70% of the world`s population. This group includes representatives from all continents and more than half of the G20 economies. In a document detailing the agreement, “all countries should gradually receive slices [of the vaccine] to cover each subset of their target groups …… until they can cover 3% of the population.” A collaboration announced earlier this month between the Serum Institute of India (SII), Gavi and the Bill and Melinda Gates Foundation will ensure that up to 100 million doses of AstraZeneca or Novavax vaccines, if successful, will be available for low- and middle-income economies through the COVAX mechanism for only $3 per dose. The arrangement also offers an option to back up additional doses if COVAX sees a need.

The separate agreements between Gavi, CEPI and AstraZeneca, announced in June, guarantee an additional 300 million doses of their vaccine candidate, if successful, for the COVAX facility. But it also means that anyone who can pay the earliest in production comes out on top of the queue, she says. And Duke`s research has found that the “vast majority” of vaccine doses purchased so far go to high-income countries. The Moderna vaccine also has fewer requirements for cold storage, which has been a problem for the poorest countries, particularly in warmer areas, isolated areas and limited electricity. Access to COVID-19 Tools ACT-Accelerator is a groundbreaking new global collaboration to accelerate development, production and equal access to COVID 19 tests, treatments and vaccines. Set up in response to a call by G20 leaders in March 2020, it was launched in April 2020 by WHO, the European Commission, France and the Bill and Melinda Gates Foundation. “We believe that international cooperation – a global effort – is crucial,” said Dag-Inge Ulstein, Norway`s Minister for International Development. We must continue to work for equal access to vaccines, testing and treatment. To defeat the coronavirus pandemic, rich countries must act quickly and courageously to provide vaccines and treatments to those who cannot afford to pay themselves. “With COVAX`s promises, we are moving in the right direction.” Coronavirus: How quickly can we count on a vaccine that works? Gavi says it has exceeded the original target of buying and distributing more than $2 billion ($1.5 billion) for the purchase and distribution of vaccines to 92 eligible countries that would otherwise not be able to afford it, but will need at least $5 billion more in 2021. Studies show that during the 2009 swine flu pandemic, vaccine supplies were dominated by pre-purchase contracts with rich countries.

“COVAX is now in business: governments on all continents have chosen to work together, not only to secure vaccines for their own people, but also to ensure that vaccines are available to the weakest of all continents,” said Dr. Seth Berkley, CEO of Gavi, the vaccination agency that coordinates the COVAX device.